Tuesday, August 18, 2020

ALBO Drops NASH Drug Development, FDA Says No To Filgotinib, SUPN On Watch, Vanda & ODYSSEY

Today's Daily Dose brings you news about another headstone in the graveyard of NASH drugs, ADC Therapeutics' near-term catalysts, Gilead's Filgotinib being turned down by the FDA, Sorrento terminating its CFO, Supernus' regulatory catalyst for November, and Vanda's progress in COVID-19 treatment Tradipitant.

from RTT - Biotech https://ift.tt/2Yc3KDm
via IFTTT

No comments:

Post a Comment